Neogen’s food-safety recovery, Lansing margin catalyst, and Zoetis debt paydown create meaningful upside—but leverage makes execution decisive.
Overview
Neogen Corporation is a global provider of food and animal health diagnostics, biosecurity chemicals, consumables, software, and genomic services. Its Food Safety segment contributes approximately 74% of sales, with the remainder from Animal Safety, and revenue is geographically balanced between domestic and international markets. The business benefits from recurring consumable demand, regulatory requirements, proprietary products such as Petrifilm and Listeria Right Now, and high switching costs created by validated testing protocols and compliance workflows. **The operating trajectory is improving:** Q4 FY2026 revenue of $225.3 million exceeded consensus by 6.01%, adjusted EPS of $0.09 beat the $0.05 estimate by 80%, and core organic revenue grew 4.3%, while Food Safety core growth reached 5.8%. FY2026 revenue was $870.4 million and adjusted EBITDA was $177.8 million, despite a reported 2.7% revenue decline. Management guides FY2027 revenue to $880-$885 million and adjusted EBITDA to $180-$182 million. **The valuation depends on execution:** the stock trades at 30.41x trailing EV/EBITDA, but the Lansing transition could add 200-300 basis points of long-term gross-margin expansion. The Zoetis genomics divestiture, expected to deliver $140 million net proceeds, and scheduled facility validation are the principal near-term catalysts. The probability-weighted five-year target is $16.64 versus a current price of $10.01.